NCT05515120View on ClinicalTrials.gov

Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 3, 2021

Primary Completion Date

January 9, 2022

Study Completion Date

July 1, 2022

Conditions
Venous ThromboembolismAnticoagulant-induced BleedingVenous ThrombosesPulmonary Embolism
Interventions
DRUG

Rivaroxaban 20 MG [Xarelto]

It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)

DRUG

Aspirin 300mg

It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)

DRUG

Acenocoumarol Oral Tablet

It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)

Trial Locations (1)

55056

Instituto Mexicano Del Seguro Social, Metepec

All Listed Sponsors
lead

Instituto Mexicano del Seguro Social

OTHER_GOV

NCT05515120 - Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events | Biotech Hunter | Biotech Hunter